Business Description
![CervoMed Inc CervoMed Inc logo](https://static.gurufocus.com/logos/0C00000DC4.png?14)
CervoMed Inc
NAICS : 325414
SIC : 2834
ISIN : US2537482067
Description
CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
Financial Strength
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.94 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 66.7 | |||||
3-Year EPS without NRI Growth Rate | 66.8 | |||||
3-Year FCF Growth Rate | 47.1 | |||||
3-Year Book Growth Rate | -64.5 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate | -72.18 |
Momentum Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 45.6 | |||||
9-Day RSI | 50.18 | |||||
14-Day RSI | 50.97 | |||||
6-1 Month Momentum % | -17.72 | |||||
12-1 Month Momentum % | 83.59 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 14.73 | |||||
Quick Ratio | 14.73 | |||||
Cash Ratio | 14.03 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -88 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -29.15 | |||||
ROA % | -25.5 | |||||
ROIC % | -471.93 | |||||
3-Year ROIIC % | -80.25 | |||||
ROCE % | -29.5 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 2.68 | |||||
Price-to-Tangible-Book | 2.68 | |||||
EV-to-EBIT | -21.28 | |||||
EV-to-Forward-EBIT | -8.35 | |||||
EV-to-EBITDA | -21.28 | |||||
EV-to-Forward-EBITDA | -7.87 | |||||
EV-to-Forward-Revenue | 13.08 | |||||
EV-to-FCF | -14.23 | |||||
Price-to-Net-Current-Asset-Value | 3.04 | |||||
Price-to-Net-Cash | 3.2 | |||||
Earnings Yield (Greenblatt) % | -4.7 | |||||
FCF Yield % | -5.7 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CRVO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
CervoMed Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | |||
EPS (TTM) ($) | -1.796 | ||
Beta | 1.46 | ||
Volatility % | 139.57 | ||
14-Day RSI | 50.97 | ||
14-Day ATR ($) | 1.945429 | ||
20-Day SMA ($) | 15.4465 | ||
12-1 Month Momentum % | 83.59 | ||
52-Week Range ($) | 4.28 - 26.3789 | ||
Shares Outstanding (Mil) | 8.25 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
CervoMed Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
CervoMed Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
CervoMed Inc Frequently Asked Questions
What is CervoMed Inc(CRVO)'s stock price today?
The current price of CRVO is $16.22. The 52 week high of CRVO is $26.38 and 52 week low is $4.28.
When is next earnings date of CervoMed Inc(CRVO)?
The next earnings date of CervoMed Inc(CRVO) is 2024-11-13 Est..
Does CervoMed Inc(CRVO) pay dividends? If so, how much?
CervoMed Inc(CRVO) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |